ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ Æ󿬱¸¼Ò 2019³Í 1Â÷½ÉÆ÷Áö¾ö : 2019-12-14 |
|
ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ Æ󿬱¸¼Ò 2019³Í 1Â÷½ÉÆ÷Áö¾ö : 2019-12-14 ±³À°ÀÏÀÚ : 2019-12-14 ±³À°Àå¼Ò : ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç ±³À°ÁÖÁ¦ : ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ Æ󿬱¸¼Ò 2019³Í 1Â÷½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ ´ã´çÀÚ : ±èº¸¹Î ¿¬¶ôó : 033-240-5265 À̸ÞÀÏ : room0939@naver.com ±³À°Á¾·ù : ³»°úÀÇ·á»çȸÇÐ Âü¼®¿¹»óÀοø : 100¸í Èñ¸ÁÆòÁ¡ : 3Á¡ Áö¿ª : °¿øµµ ±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ ¼¼ºÎ¼ö°·á : 10,000¿ø ºñ°í ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 15:00~15:40 ÀÇ·á¿Í ¼¼»ó ±Çº¹±Ô(ÀÌÈ¿©´ë ÀÇ°ú´ëÇÐ) ÈÞ½Ä 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 15:40~16:00 Break time () ±³À°½Ã°£ 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 16:00~16:30 Biomarkers in lung cancer screening ¹ÚÁö¿µ(ÇѸ²´ë ¼º½Éº´¿ø) ±³À°½Ã°£ 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 16:30~17:00 Tuberculosis and lung damage ÃÖÇÏ¿µ(ÇѸ²´ë °³²¼º½Éº´¿ø) ÈÞ½Ä 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 17:00~17:10 Break time () ±³À°½Ã°£ 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 17:10~17:40 Biologics in severe asthma ¹Ý°¡¿µ(ÇѸ²´ë °µ¿¼º½Éº´¿ø) ±³À°½Ã°£ 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 17:40~18:10 Eosinophil in COPD ±èÀ¯¸²(ÇѸ²´ë Ãáõ¼º½Éº´¿ø) ±³À°½Ã°£ 12-14 ÇѸ²´ëÇб³ ±¹Á¦È¸ÀÇ½Ç 18:10~18:30 Æ󿬱¸¼Ò °øµ¿ ¿¬±¸ Á¦¾È ÀÌâ·ü(ÇѸ²´ë Ãáõ¼º½Éº´¿ø) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|
Á¦¸ñ |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 239 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 137 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 134 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 134 , ´ñ±Û¼ö : 0 |
Ãßõ¼ö : 0 , Á¶È¸¼ö : 249 , ´ñ±Û¼ö : 0 |